8-K: Silexion Reports Strong Preclinical Data, Q2 2025 Results

Silexion Therapeutics announced strong preclinical efficacy for its SIL204 program across multiple KRAS-driven cancers and reported its second-quarter 2025 financial results.

Summary

• Strong preclinical data for SIL204 demonstrated up to 94% inhibition in pancreatic cancer cells (KRAS G12D), approximately 90% inhibition in colorectal cancer cells (KRAS G12D), and significant dose-dependent inhibition in human lung cancer cell lines (KRAS G12D).
• First evidence of SIL204's efficacy against the clinically significant KRAS Q61H mutation was reported, showing up to 97% inhibition in pancreatic cancer cells.
• A strategic formulation partnership was announced with Catalent for SIL204 development and clinical manufacturing.
• The company remains on track to initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026, focusing initially on locally advanced pancreatic cancer.
• Regulatory submissions to initiate the Phase 2/3 trial are planned for the Israel Ministry of Health in Q4 2025 and the European Union in Q1 2026.
• Nasdaq listing was maintained following a favorable decision from a Nasdaq hearings panel, and a 1-for-15 reverse share split was effected on July 29, 2025.
• Approximately $1.8 million in gross proceeds were generated from a warrant exercise inducement transaction on July 31, 2025.
• Cash and cash equivalents were $3.5 million as of June 30, 2025, an increase from $1.2 million as of December 31, 2024.
• Net loss for the second quarter ended June 30, 2025, was $2.5 million, compared to $1.5 million for the same period in 2024.
• Total operating expenses for Q2 2025 were $2.3 million, an increase from $1.4 million in Q2 2024.
• Net loss for the six months ended June 30, 2025, was $4.2 million, compared to $2.9 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The strong preclinical data and clear path to clinical trials are significant positives for a biotech company, indicating scientific progress. The successful maintenance of Nasdaq listing and recent capital raise also provide stability. However, the increasing operating expenses and net loss reflect the high burn rate typical of early-stage drug development, which introduces financial risk.

Positives

• Strong preclinical efficacy data for SIL204 across multiple KRAS-driven cancer types (pancreatic, colorectal, lung), including new KRAS Q61H mutation coverage with up to 97% inhibition.
• Strategic formulation partnership with Catalent supports dual-route development and clinical manufacturing activities for SIL204.
• Maintained Nasdaq listing, ensuring continued access to public markets and investor confidence.
• Generated approximately $1.8 million in gross proceeds from a warrant exercise inducement transaction, strengthening the financial position.
• Progressing as planned towards Phase 2/3 clinical trials in the first half of 2026, indicating advancement in the drug development pipeline.

Negatives

• Net loss for Q2 2025 increased by 66.7% to $2.5 million compared to $1.5 million in Q2 2024.
• Total operating expenses for Q2 2025 increased by 64.3% to $2.3 million compared to $1.4 million in Q2 2024.
• General and administrative expenses for Q2 2025 increased by 116.7% to $1.3 million compared to $0.6 million in Q2 2024, mainly due to public company operating costs.
• Research and development expenses for Q2 2025 increased by 25.0% to $1.0 million compared to $0.8 million in Q2 2024, due to increased payroll and bonus accrual.
• Financial expenses, net for Q2 2025 increased by 100.0% to $0.2 million compared to $0.1 million in Q2 2024.
• Accumulated deficit increased to $47.492 million as of June 30, 2025, from $43.254 million as of December 31, 2024.
• The company continues to work toward achieving the required $2.5 million shareholders' equity threshold for Nasdaq compliance.

Risks

• Ability to successfully complete preclinical studies and initiate clinical trials.
• Company's strategy, future operations, financial position, projected costs, prospects, and plans.
• Impact of the regulatory environment and compliance complexities.
• Expectations regarding future partnerships or other relationships with third parties.
• Future capital requirements and sources and uses of cash, including the ability to obtain additional capital.
• Ability to maintain Nasdaq listing.
• Other risks and uncertainties set forth in documents filed or to be filed with the SEC, including the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025.

Future Outlook

Silexion remains on track to initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026, initially targeting locally advanced pancreatic cancer. Regulatory submissions are planned for the Israel Ministry of Health in Q4 2025 and the European Union in Q1 2026. The company is also conducting toxicology studies which are progressing as planned.

Management Comments

• "The second quarter of 2025 marked a transformative period for Silexion as we significantly expanded the potential therapeutic applications of SIL204 beyond pancreatic cancer."
• "Our preclinical data now demonstrates SIL204's impressive efficacy across pancreatic, colorectal, and lung cancers three of the most challenging KRAS-driven malignancies."
• "With high inhibition rates and coverage of multiple KRAS mutations including the newly validated Q61H and G13D variants, SIL204 is positioned as a potentially transformative pan-KRAS therapeutic."
• "The strategic collaboration with Catalent and our continued progress toward clinical trials in 2026 reinforce our commitment to bringing this innovative RNAi therapy to patients with limited treatment options."
• "As we advance our dual-route administration strategy and maintain our Nasdaq listing, we remain focused on executing our clinical development plan and delivering value to both patients and shareholders."

Industry Context

Silexion Therapeutics operates in the highly competitive and innovative biotechnology sector, specifically focusing on RNA interference (RNAi) therapies for KRAS-driven cancers. KRAS mutations are notoriously difficult to target, making Silexion's preclinical efficacy data across multiple cancer types a significant development in the oncology landscape. The strategic partnership with Catalent aligns with industry trends of outsourcing specialized manufacturing and formulation to accelerate drug development.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking.
• The reported preclinical inhibition rates of up to 97% for KRAS mutations are highly promising within the oncology drug development space, where KRAS has historically been considered 'undruggable'.
• Success in early-stage biotech is often measured by the strength of preclinical data and progression to clinical trials, which Silexion is achieving.
• The company's financial position, while improved by recent financing, reflects the typical high burn rate of a clinical-stage biotech company, which is standard for the industry as R&D and G&A expenses increase with development.

Corporate Governance

Related Party Transactions

• Research and development expenses included $0 from related party for the six months ended June 30, 2025 (vs $34k in 2024) and $0 for the three months ended June 30, 2025 (vs $17k in 2024).
• General and administrative expenses included $58k from related party for the six months ended June 30, 2025 (vs $24k in 2024) and $37k for the three months ended June 30, 2025 (vs $12k in 2024).
• Financial expenses, net included $229k from related party for the six months ended June 30, 2025 (vs $135k in 2024) and $197k for the three months ended June 30, 2025 (vs $60k in 2024).
• A Related Party Promissory Note of $3.190 million as of June 30, 2025 (vs $2.961 million as of December 31, 2024).

Stakeholder Impact

• Shareholders: Potential for long-term value creation if SIL204 progresses successfully through clinical trials; immediate impact from 1-for-15 reverse share split and warrant exercise; improved shareholders' equity position.
• Patients: Potential for a new, transformative RNAi therapy for difficult-to-treat KRAS-driven cancers, offering new treatment options.
• Employees: Increased headcount and salary increases contributing to higher payroll expenses.
• Creditors: Long-term operating lease liability and Related Party Promissory Note represent ongoing obligations.

Next Steps

• Conduct toxicology studies for SIL204 (progressing as planned).
• Regulatory submission to Israel Ministry of Health in Q4 2025 for Phase 2/3 trial.
• Regulatory submission to European Union in Q1 2026 for Phase 2/3 trial.
• Initiate Phase 2/3 clinical trials for SIL204 in the first half of 2026, focusing initially on locally advanced pancreatic cancer.
• Work toward achieving the required $2.5 million shareholders' equity threshold for Nasdaq compliance.

Key Dates

Recommendation

Silexion Therapeutics presents a high-risk, high-reward profile typical of early-stage biotech. The strong preclinical data for SIL204 across multiple KRAS-driven cancer types, including new mutation coverage, is a significant positive and de-risks the scientific aspect to some extent. The strategic partnership with Catalent and the clear timeline for Phase 2/3 clinical trials in H1 2026 are also encouraging. However, the company's financial position shows increasing operating expenses and net losses, which is expected for a development-stage company but highlights the ongoing need for capital. While the recent warrant exercise provided $1.8 million, the company still needs to achieve a $2.5 million shareholders' equity threshold for Nasdaq compliance. Given the promising scientific progress balanced by the inherent financial burn and regulatory hurdles of clinical development, a 'hold' recommendation is appropriate for investors already in, while new investors should consider the significant risk associated with early-stage biotech before initiating a position.

Keywords

Silexion Therapeutics, SLXN, RNA interference, RNAi, KRAS-driven cancers, pancreatic cancer, colorectal cancer, lung cancer, SIL204, preclinical data, clinical trials, biotechnology, oncology, Nasdaq listing, financial results, warrant exercise